Since 2017, MMGH has provided ongoing support to the WHO Expanded Program on Immunisation’s MI4A initiative aimed at enhancing countries’ access to safe, effective, quality, and affordable vaccines. MMGH consults with manufacturers, defines the methodological aspects of the studies, evaluates current and future supply, identifies bottlenecks on the supply-demand balance, and proposes mitigating measures. To-date, the project has produced market studies for Bacillus Calmette-Guerin (BCG), Human papillomavirus (HPV), Meningococcal meningitis, Diphtheria & Tetanus-containing, Measles-containing, Pneumococcal, Typhoid and Rabies vaccines. In 2021, the project has focused on evaluating the risks and impacts of the SARS-Cov-2 pandemic and COVID-19 vaccine production to the access and availability of vaccines for routine immunisation.